Biogen Idec, Inc. v. GlaxoSmithKline LLC (Fed. Cir. 2013) Patent Docs The examiner acknowledged that the specification was enabling for Biogen's chimeric gamma 1 anti-human CD20 antibody, Rituxan® (rituximab), but was silent concerning the specificity and affinity that would be necessary for other anti-CD20 antibodies. |
